Decoding Refractory GERD and the Role of Vonoprazan - Dr Ajay Kumar

Gastroesophageal reflux disease (GERD) occurs when stomach acid flows back into the esophagus due to a weak lower esophageal sphincter. There is no specific treatment to strengthen the sphincter, but we have medications that reduce stomach acid, thereby lessening symptoms. However, with the increasing incidence of GERD, more cases of refractory GERD are emerging. This type of severe GERD does not respond to regular proton pump inhibitors (PPIs). While PPIs typically help heal esophageal damage and relieve symptoms, up to 40% of GERD patients do not respond adequately to this treatment, making refractory GERD a significant challenge.

In this video, Dr Ajay Kumar, Chairman of Gastroenterology & Hepatology at Pan Max and Head of Department at BLK Institute for Digestive & Liver Diseases, BLK-Max Super Speciality Hospital, New Delhi, shares his insights into GERD management, the challenges of treating refractory GERD, and innovative approaches that can improve patient outcomes.

Key Questions Discussed:

1) Why is refractory GERD a growing problem?

2) What unmet needs exist with current therapies for refractory GERD?

3) How does Vonoprazan address the current gaps in GERD management?